185 related articles for article (PubMed ID: 22187040)
1. BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML.
Lin WH; Jiaang WT; Chen CW; Yen KJ; Hsieh SY; Yen SC; Chen CP; Chang KY; Chang CY; Chang TY; Huang YL; Yeh TK; Chao YS; Chen CT; Hsu JT
Br J Cancer; 2012 Jan; 106(3):475-81. PubMed ID: 22187040
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.
Lin WH; Yeh TK; Jiaang WT; Yen KJ; Chen CH; Huang CT; Yen SC; Hsieh SY; Chou LH; Chen CP; Chiu CH; Kao LC; Chao YS; Chen CT; Hsu JT
PLoS One; 2014; 9(1):e83160. PubMed ID: 24416160
[TBL] [Abstract][Full Text] [Related]
3. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
Shankar DB; Li J; Tapang P; Owen McCall J; Pease LJ; Dai Y; Wei RQ; Albert DH; Bouska JJ; Osterling DJ; Guo J; Marcotte PA; Johnson EF; Soni N; Hartandi K; Michaelides MR; Davidsen SK; Priceman SJ; Chang JC; Rhodes K; Shah N; Moore TB; Sakamoto KM; Glaser KB
Blood; 2007 Apr; 109(8):3400-8. PubMed ID: 17209055
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo.
Xu Y; Wang NY; Song XJ; Lei Q; Ye TH; You XY; Zuo WQ; Xia Y; Zhang LD; Yu LT
Bioorg Med Chem; 2015 Aug; 23(15):4333-4343. PubMed ID: 26142317
[TBL] [Abstract][Full Text] [Related]
5. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Keegan K; Li C; Li Z; Ma J; Ragains M; Coberly S; Hollenback D; Eksterowicz J; Liang L; Weidner M; Huard J; Wang X; Alba G; Orf J; Lo MC; Zhao S; Ngo R; Chen A; Liu L; Carlson T; Quéva C; McGee LR; Medina J; Kamb A; Wickramasinghe D; Dai K
Mol Cancer Ther; 2014 Apr; 13(4):880-9. PubMed ID: 24526162
[TBL] [Abstract][Full Text] [Related]
7. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK
Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
[TBL] [Abstract][Full Text] [Related]
10. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
[TBL] [Abstract][Full Text] [Related]
12. Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsieh SY; Yen SC; Chen CT; Yeh TK; Hsu T; Lu CT; Chen CP; Chen CW; Chou LH; Huang YL; Cheng AH; Chang YI; Tseng YJ; Yen KR; Chao YS; Hsu JT; Jiaang WT
Bioorg Med Chem; 2011 Jul; 19(14):4173-82. PubMed ID: 21708468
[TBL] [Abstract][Full Text] [Related]
13. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
[TBL] [Abstract][Full Text] [Related]
14. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Potent and Selective FLT3 Inhibitor (
Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
[TBL] [Abstract][Full Text] [Related]
16. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
17. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.
Nordigården A; Zetterblad J; Trinks C; Gréen H; Eliasson P; Druid P; Lotfi K; Rönnstrand L; Walz TM; Jönsson JI
Br J Haematol; 2011 Oct; 155(2):198-208. PubMed ID: 21848891
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
[TBL] [Abstract][Full Text] [Related]
19. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
20. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]